These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 5829925)

  • 21. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further observations on 17D-yellow fever vaccination by scarification, with and without simultaneous smallpox vaccination.
    MEERS PD
    Trans R Soc Trop Med Hyg; 1960 Sep; 54():493-501. PubMed ID: 13768949
    [No Abstract]   [Full Text] [Related]  

  • 23. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination.
    Martins MA; Silva ML; Elói-Santos SM; Ribeiro JG; Peruhype-Magalhães V; Marciano AP; Homma A; Kroon EG; Teixeira-Carvalho A; Martins-Filho OA
    Vaccine; 2008 Feb; 26(9):1173-84. PubMed ID: 18243433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mass vaccination with the Rockefeller 17 D strain vaccine in Senegal. Use of "Ped-o-Jet"].
    Artus JC
    Med Trop (Mars); 1966; 26(5):527-36. PubMed ID: 5976660
    [No Abstract]   [Full Text] [Related]  

  • 25. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.
    Kengsakul K; Sathirapongsasuti K; Punyagupta S
    J Med Assoc Thai; 2002 Jan; 85(1):131-4. PubMed ID: 12075714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Yellow fever vaccination as prophylaxis of herpes labialis].
    Møller A; Andersen PL; Korsager B; Black FT
    Ugeskr Laeger; 1997 Apr; 159(15):2228-9. PubMed ID: 9148548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination against mosquito borne viral infections: current status.
    Wiwanitkit V
    Iran J Immunol; 2007 Dec; 4(4):186-96. PubMed ID: 18057576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute viscerotropic disease following vaccination against yellow fever.
    Hayes EB
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
    Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
    Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Present status of an arbovirus infection: yellow fever, its natural history of hemorrhagic fever, Rift Valley fever].
    Digoutte JP
    Bull Soc Pathol Exot; 1999 Dec; 92(5):343-8. PubMed ID: 10690474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yellow fever vaccination by scarification with the 17D strain: an appreciation of the present position.
    MEERS PD
    Trans R Soc Trop Med Hyg; 1957 Jul; 51(4):338-45. PubMed ID: 13455700
    [No Abstract]   [Full Text] [Related]  

  • 36. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates.
    McGee CE; Lewis MG; Claire MS; Wagner W; Lang J; Guy B; Tsetsarkin K; Higgs S; Decelle T
    J Infect Dis; 2008 Mar; 197(5):693-7. PubMed ID: 18266603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-yellow fever vaccination].
    Franco O
    Rev Bras Malariol Doencas Trop; 1965; 17(1):75-81. PubMed ID: 5860036
    [No Abstract]   [Full Text] [Related]  

  • 38. Compatible concurrent administration of yellow fever 17D vaccine with oral, live, attenuated p6olera CVD103-HgR and typhoid ty21a vaccines.
    Tsai TF; Kollaritsch H; Que JU; Cropp CB; Kunz C; Wiedermann G; Herzog C; Cryz SJ
    J Infect Dis; 1999 Feb; 179(2):522-4. PubMed ID: 9878043
    [No Abstract]   [Full Text] [Related]  

  • 39. Yellow fever vaccination by scarification with 17D vaccine.
    DE ROEVER-BONNET H; HOEKSTRA J
    Trop Geogr Med; 1958 Sep; 10(3):289-91. PubMed ID: 13603603
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe post-vaccination reaction to 17D yellow fever vaccine in Nigeria.
    Oyelami SA; Olaleye OD; Oyejide CO; Omilabu SA; Fatunla BA
    Rev Roum Virol; 1994; 45(1-2):25-30. PubMed ID: 7756161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.